文献速递免疫规划传染病防控与疫情报告

基于比利时接触者追踪的2021年SARS-CoV-2感染续发传播疫苗有效性研究:按需关注变异株和接种后时间分析

Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021.
PubMed 文献 · Vaccine · 2022-04-12

该研究利用比利时2021年1月26日至12月14日接触者追踪数据,采用多水平贝叶斯模型估计完整接种Ad26.COV2.S、ChAdOx1、BNT162b2、mRNA-1273及感染获得和混合免疫对SARS-CoV-2感染续发传播的疫苗有效性(VET),分解为易感性(VEs)和突破病例传染性(VEi)。结果显示mRNA疫苗VET超过90%,病毒载体疫苗较低;Delta变异株使传播比值增加40%并降低VEs和VEi,且随时间减弱,老年组初始VEi更低且减弱更快。

要点

  • mRNA疫苗VET超过90%,Ad26.COV2.S和ChAdOx1分别为66%和80%(Alpha,接种后0-50天)。
  • Delta与传播比值增加40%相关,并降低VEs(72-64%)和VEi(BNT162b2为71-46%)。
  • BNT162b2的VET从81%降至63%(Delta,接种后150-200天),65-84岁组初始VEi为32% vs 45-64岁组46%。

核心结论

  • VEi和VEs估计值虽仍显著,但被Delta降低并随时间减弱,最年长组减弱更快。
  • 应设法改善老年人和接种病毒载体疫苗者的疫苗诱导保护。

研究设计与样本

  • 利用比利时2021年1月26日至12月14日接触者追踪数据,估计完整接种Ad26.COV2.S、ChAdOx1、BNT162b2、mRNA-1273及感染获得和混合免疫对SARS-CoV-2感染续发传播的疫苗有效性(VET)。
  • 采用多水平贝叶斯模型,调整年龄、性别、家庭、背景暴露、日历周、需关注变异株和免疫 conferring 事件后时间。

主要发现

  • mRNA疫苗VET估计值超过90%,高于病毒载体疫苗:Ad26.COV2.S为66%,ChAdOx1为80%(Alpha,接种后0-50天)。
  • Delta与传播比值增加40%相关,并降低VEs(72-64%)和尤其VEi(BNT162b2为71-46%)。
  • 感染获得和混合免疫受Delta影响较小。
  • VET随时间减弱:BNT162b2从81%降至63%(Delta,接种后150-200天)。
  • 65-84岁组初始VEi较低(BNT162b2为32% vs 45-64岁组46%)且减弱更快;混合免疫减弱慢于疫苗诱导免疫。

临床怎么用

  • 作者认为应设法改善老年人和接种病毒载体疫苗者的疫苗诱导保护。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: During the first half of 2021, we observed high vaccine effectiveness (VE) against SARS-CoV2-infection. The replacement of the alpha-'variant of concern' (VOC) by the delta-VOC and uncertainty about the time course of immunity called for a re-assessment. METHODS: We estimated VE against transmission of infection (VET) from Belgian contact tracing data for high-risk exposure contacts between 26/01/2021 and 14/12/2021 by susceptibility (VEs) and infectiousness of breakthrough cases (VEi) for a complete schedule of Ad26.COV2.S, ChAdOx1, BNT162b2, mRNA-1273 as well as infection-acquired and hybrid immunity. We used a multilevel Bayesian model and adjusted for personal characteristics (age, sex, household), background exposure, calendar week, VOC and time since immunity conferring-event. FINDINGS: VET-estimates were higher for mRNA-vaccines, over 90%, compared to viral vector vaccines: 66% and 80% for Ad26COV2.S and ChAdOx1 respectively (Alpha, 0-50 days after vaccination). Delta was associated with a 40% increase in odds of transmission and a decrease of VEs (72-64%) and especially of VEi (71-46% for BNT162b2). Infection-acquired and hybrid immunity were less affected by Delta. Waning further reduced VET-estimates: from 81% to 63% for BNT162b2 (Delta, 150-200 days after vaccination). We observed lower initial VEi in the age group 65-84 years (32% vs 46% in the age group 45-64 years for BNT162b2) and faster waning. Hybrid immunity waned slower than vaccine-induced immunity. INTERPRETATION: VEi and VEs-estimates, while remaining significant, were reduced by Delta and waned over time. We observed faster waning in the oldest age group. We should seek to improve vaccine-induced protection in older persons and those vaccinated with viral-vector vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Braeye T, Catteau L, Brondeel R, et al. Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021. Vaccine. 2022. PMID: 35459558. doi:10.1016/j.vaccine.2022.04.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。